Eyal Ben Ami

Eyal Ben Ami, PhD, MBA, joined M Ventures in July 2022 and is currently an Associate in the Biotechnology team. Prior to joining M Ventures, Eyal served as the CSO at MOYA Bio where he led the development of novel anti-neoplastic compounds in the field of protein degradation. Prior to this, he had served in various roles at BiolineRx and ImmunoBrain Therapies, managing the development of multiple immunotherapy programs from early discovery stages through clinical translation. Eyal holds a PhD in Neuroimmunology from the Technion in Israel, followed by a research fellowship at UPMC in Paris, as well as an MSc in Biotechnology form the Hebrew University and an executive MBA from Tel Aviv University. He is based in Yavne.